Poly Medicure Ltd

Poly Medicure announced that the Board of Directors of the Company at its meeting held on 6 May 2025, inter alia, have recommended the final dividend of Rs 3.5 per equity Share (i.e. 70%) , subject to the approval of the shareholders.Powered by Capital Market - Live

Net profit of Poly Medicure rose 34.33% to Rs 91.83 crore in the quarter ended March 2025 as against Rs 68.36 crore during the previous quarter ended March 2024. Sales rose 16.60% to Rs 440.83 crore in the quarter ended March 2025 as against Rs 378.07 crore during the previous quarter ended March 2024. For the full year,net profit rose 31.09% to Rs 338.56 crore in the year ended March 2025 as against Rs 258.26 crore during the previous year ended March 2024. Sales rose 21.37% to Rs 1669.83 crore in the year ended March 2025 as against Rs 1375.80 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales440.83378.07 17 1669.831375.80 21 OPM %27.1025.51 -27.1226.00 - PBDT143.88108.54 33 535.15407.71 31 PBT122.8592.46 33 452.52344.27 31 NP91.8368.36 34 338.56258.26 31 Powered by Capital Market - Live

Poly Medicure will hold a meeting of the Board of Directors of the Company on 6 May 2025.Powered by Capital Market - Live

Poly Medicure has incorporated a wholly owned Step down subsidiary named Polyhealth in England and Wales on 04 February 2025. Polyhealth will be engaged in maufacturing and distribution of Medical Devices with great experiences for its customers. The focus will be on the supply chain and cater the Medical Devices market and/or any other activities ancillary and incidental thereto in in England and wales and other parts of Europe also. Powered by Capital Market - Live

The revenue growth was driven by the firm's robust market presence and effective growth strategies. Profit before tax increased 28.93% year on year (YoY) to Rs 113.23 crore in the quarter ended 31 December 2023. EBITDA grew 27.9% YoY to Rs 116.3 crore during the quarter. EBITDA margin improved to 27.4% in Q3 FY25, compared to 26.8% posted in Q3 FY24. Total expenses in Q3 FY25 were at Rs 334.51 crore, up 24.33% YoY. Cost of materials consumed was Rs 141.95 crore (up 19.57% YoY) while employee benefits expense stood at Rs 77.89 crore (up 28.96% YoY) during the period under review. On nine-month basis, the company's consolidated net profit climbed 29.92% to Rs 246.72 crore on 23.18% rise in revenue to Rs 1,229 crore in Q3 FY25 over Q3 FY24. Export revenue for the nine months increased by 29% YoY, driven by continued strong performance in key international markets. The domestic quarterly and nine-month revenue growth of 24% and 17% YoY respectively on a YoY basis, demonstrating the company's continued investments in building R&D and sales capabilities. Himanshu Baid, managing director, Poly Medicure stated: 'We are extremely pleased with our continued growth in the business in the last quarter. Overall revenue grew by almost 25% with EBITDA and PAT growing by 28% and 31% respectively. We are on track to achieve our revenue growth guidance of 22-24% while improving our EBITDA margin by 100 ' 150 bps. I am very excited to share that we have received regulatory approval to launch our Drug Eluting Stent and commercialisation of that is expected soon. That will give a significant fillip to our Cardiology business. We continue to invest aggressively in building our manufacturing capacities and recently ground-breaking ceremony was held at our Palwal Plant, which will be the largest plant that we would be seƫng up at a single location. We have also signed a JV agreement to set up a 10MW Solar Power plant in Haryana where we will own 26% stake. This will go a long way in achieving our sustainability goals and reduce our carbon-footprint. We are very excited about the growth opportunity that India provides in the MedTech sector and our continued investments strongly reflects in that belief.' Poly Medicure exports plastic medical disposables/surgical devices. It manufactures and supplies approximately 100 types of disposable medical devices in the product verticals of infusion therapy, anesthesia, urology, gastroenterology, blood management and blood collection, surgery and wound drainage, dialysis and central venous access catheters. Powered by Capital Market - Live

NLC India Ltd, Prudent Corporate Advisory Services Ltd, Redtape Ltd and Nuvama Wealth Management Ltd are among the other gainers in the BSE's 'A' group today, 04 February 2025.Poly Medicure Ltd soared 10.29% to Rs 2518.55 at 11:48 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 9522 shares were traded on the counter so far as against the average daily volumes of 6553 shares in the past one month. NLC India Ltd surged 10.25% to Rs 232.9. The stock was the second biggest gainer in 'A' group. On the BSE, 7.94 lakh shares were traded on the counter so far as against the average daily volumes of 75652 shares in the past one month. Prudent Corporate Advisory Services Ltd spiked 9.42% to Rs 2199.3. The stock was the third biggest gainer in 'A' group. On the BSE, 4479 shares were traded on the counter so far as against the average daily volumes of 3548 shares in the past one month. Redtape Ltd jumped 9.39% to Rs 198. The stock was the fourth biggest gainer in 'A' group. On the BSE, 52286 shares were traded on the counter so far as against the average daily volumes of 9962 shares in the past one month. Nuvama Wealth Management Ltd gained 8.70% to Rs 5551.05. The stock was the fifth biggest gainer in 'A' group. On the BSE, 7669 shares were traded on the counter so far as against the average daily volumes of 7409 shares in the past one month. Powered by Capital Market - Live

Net profit of Poly Medicure rose 31.08% to Rs 85.23 crore in the quarter ended December 2024 as against Rs 65.02 crore during the previous quarter ended December 2023. Sales rose 24.91% to Rs 424.21 crore in the quarter ended December 2024 as against Rs 339.60 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales424.21339.60 25 OPM %27.0026.57 - PBDT134.74104.04 30 PBT113.2387.82 29 NP85.2365.02 31 Powered by Capital Market - Live

Poly Medicure will hold a meeting of the Board of Directors of the Company on 3 February 2025.Powered by Capital Market - Live

Poly Medicure has entered into a joint venture agreement with AMPIN C&I Power for the purpose of setting up a Solar Power Project, which will be set up to supply power to the Company as a captive generating plant for Company's manufacturing facility, in Haryana, India. Pursuant to the said JV Agreement, the proposed JV Company will be 26% owned by Poly Medicure and 74% owned by AMPIN C&I Power. Powered by Capital Market - Live

Adani Green Energy Ltd, DCM Shriram Ltd, Fortis Healthcare Ltd and Emami Ltd are among the other losers in the BSE's 'A' group today, 26 November 2024.Poly Medicure Ltd tumbled 7.27% to Rs 2784.4 at 14:47 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 21486 shares were traded on the counter so far as against the average daily volumes of 14968 shares in the past one month.Adani Green Energy Ltd lost 6.47% to Rs 905. The stock was the second biggest loser in 'A' group.On the BSE, 3.82 lakh shares were traded on the counter so far as against the average daily volumes of 2.73 lakh shares in the past one month.DCM Shriram Ltd crashed 5.49% to Rs 1159.95. The stock was the third biggest loser in 'A' group.On the BSE, 19312 shares were traded on the counter so far as against the average daily volumes of 15940 shares in the past one month.Fortis Healthcare Ltd plummeted 4.92% to Rs 666.25. The stock was the fourth biggest loser in 'A' group.On the BSE, 49929 shares were traded on the counter so far as against the average daily volumes of 46145 shares in the past one month.Emami Ltd corrected 4.27% to Rs 663.45. The stock was the fifth biggest loser in 'A' group.On the BSE, 18549 shares were traded on the counter so far as against the average daily volumes of 17507 shares in the past one month.Powered by Capital Market - Live